Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: NASH, dyslipidemia, inflammation, diabetic nephropathy, HFpEF and atherosclerosis.

For >20 years, we have been evaluating the efficacy of our clients' drugs using gold-standard experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated by our numerous co-publications with our industrial partners.

Our expertise – your success.

www.physiogenex.com